What price per share was used in the RIGL tax-withholding transaction?

The tax-withholding transaction used a price of $34.62 per Rigel Pharmaceuticals common share. This value determines how many shares were needed to cover the executive’s tax obligation tied to her equity compensation event.

Rigel EVP logs tax-related stock withholding

Rigel Pharmaceuticals executive Lisa Rojkjaer reported a tax-related stock transaction.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Rigel Pharmaceuticals executive Lisa Rojkjaer reported a tax-related stock transaction. As EVP and Chief Medical Officer, she disposed of 3,758 shares of common stock on February 10, 2026 through a tax-withholding arrangement at $34.62 per share.

After this transaction, she directly beneficially owned 15,959 shares of Rigel Pharmaceuticals common stock. The transaction was coded as a payment of tax liability by delivering securities, which is typically associated with equity compensation events rather than an open-market sale.

Insider Trade Summary

Exercise Price or Tax Liability: 3,758 shares

Exercise Price or Tax Liability 1 txn

Insider Rojkjaer Lisa

Role EVP, Chief Medical Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	3,758	$34.62	$130K

Holdings After Transaction: Common Stock — 15,959 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RIGL executive Lisa Rojkjaer report?

Lisa Rojkjaer reported a tax-related disposition of Rigel Pharmaceuticals common stock. On February 10, 2026, 3,758 shares were withheld at $34.62 per share to cover tax obligations associated with equity compensation.

How many Rigel (RIGL) shares were involved in Lisa Rojkjaer’s Form 4?

The Form 4 shows 3,758 shares of Rigel Pharmaceuticals common stock were disposed of. The transaction was coded as tax-withholding, meaning shares were used to satisfy tax liabilities rather than sold in an open market trade.

How many Rigel (RIGL) shares does Lisa Rojkjaer own after the transaction?

After the reported tax-withholding disposition, Lisa Rojkjaer directly beneficially owned 15,959 shares of Rigel Pharmaceuticals common stock. This reflects her remaining equity stake following the 3,758 shares used to satisfy tax liabilities.

Was the RIGL insider transaction a market sale or tax withholding?

The transaction was tax withholding rather than a market sale. It is coded “F,” defined as payment of an exercise price or tax liability by delivering securities, commonly linked to vesting or exercise of equity awards.

What role does Lisa Rojkjaer hold at Rigel Pharmaceuticals (RIGL)?

Lisa Rojkjaer serves as Executive Vice President and Chief Medical Officer at Rigel Pharmaceuticals. Her position and equity holdings are disclosed in the Form 4 insider report documenting the February 10, 2026 tax-withholding stock transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/12/2026 - 04:50 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rojkjaer Lisa

(Last)

(First)

(Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/10/2026		F		3,758	D	$34.62	15,959	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Raymond Furey (Attorney-in-Fact)	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR